Gastroretentive dosage forms: Overview and special case of Helicobacter pylori

Journal of Controlled Release

Volumn 111, Issue 1-2, 2006, Pages 1-18

  Bardonnet, P L ^a,b   Faivre, V ^a,e   Pugh, W J ^c   Piffaretti, J C ^d   Falson, F ^a  

^a UNIVERSITÉ LYON 1   (France)

^b Universities of Geneva and Lyon   (France)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d Istituto Cantonale di Microbiologia   (Switzerland)

^e UNIV PARIS SUD   (France)

Author keywords

Adhesive systems; Gastroretentive forms; Helicobacter pylori; Specific targeting

Indexed keywords

ADHESIVES; BACTERIOLOGY; GASTROENTEROLOGY; HYDROGELS; PHYSIOLOGICAL MODELS;

ADHESIVE SYSTEMS; GASTRORETENTIVE FORMS; HELICOBACTER PYLORI; SPECIFIC TARGETING;

DRUG DOSAGE;

4 NITROANILINE; ACETYLSALICYLIC ACID; AGAR; ALGINIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BENSERAZIDE PLUS LEVODOPA; CALCIUM ALGINATE; CARBIDOPA PLUS LEVODOPA; CARBOMER; CARBOXYMETHYLCELLULOSE; CARRAGEENAN; CELLULOSE ACETATE; CHLORPHENIRAMINE MALEATE; CROSCARMELLOSE SODIUM; DILTIAZEM; EUDRAGIT; EUDRAGIT RS; GANTREZ; GAVISCON; GELATIN; GRISEOFULVIN; HYDROXYETHYLCELLULOSE; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; IBUPROFEN; MADOPAR LP; MICROSPHERE; MISOPROSTOL; PECTIN; POLYCARBONATE; POLYMER; RIBOFLAVIN; TRANILAST; UNINDEXED DRUG;

BACTERIAL COLONIZATION; CANCER RISK; CONTROLLED DRUG RELEASE; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG CAPSULE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG PENETRATION; DRUG RETENTION; ENCAPSULATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ABSORPTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HYDROGEL; LIPOPHILICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; STOMACH MUCUS; STOMACH ULCER;

EID: 33344460381     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2005.10.031     Document Type: Review

References (175)

1. R. Gröning, and G. Heun Oral dosage forms with controlled gastrointestinal transit Drug. Dev. Ind. Pharm. 10 1984 527 539
2. A.J. Moes Gastroretentive dosage forms Crit. Rev. Ther. Drug Carr. Syst. 10 2 1993 143 195
3. A.A. Deshpande, C.T. Rhodes, N.H. Shah, and A.W. Malick Controlled release drug delivery systems for prolonged gastric residence: an overview Drug Dev. Ind. Pharm. 22 6 1996 531 539
4. A.F. Goddard, and R.P. Logan Diagnostic methods for Helicobacter pylori detection and eradication Br. J. Clin. Pharmacol. 56 3 2003 273 283
5. S. Schreiber, M. Konradt, C. Groll, P. Scheid, G. Hanauer, H.O. Werling, C. Josenhans, and S. Suerbaum The spatial orientation of Helicobacter pylori in the gastric mucus Proc. Natl. Acad. Sci. U. S. A. 101 14 2004 5024 5029
6. 14C]amoxicillin in rat gastric tissue when administered with lansoprazole and clarithromycin J. Antimicrob. Chemother. 48 6 2001 923 926
7. 14C]clarithromycin in rat gastric tissue when administered with lansoprazole and amoxicillin J. Antimicrob. Chemother. 50 2 2002 285 288
8. J.J. Bernier, J. Adrian, and N. Vidon Les aliments dans le tube digestif 1988 Doin Paris
9. H. Guénard Physiologie humaine 2e édition 1996 Pradel Paris
10. J. Timmermans, and A.J. Moes The cutoff size for gastric emptying of dosage forms J. Pharm. Sci. 82 8 1993 854
11. C. Dubernet Systèmes à libération gastrique prolongée F. Falson-Rieg V. Faivre F. Pirot Nouvelles formes médicamenteuses, Éditions Médicales Internationales 2004 Éditions TEC and DOC Cachan 119 133
12. J.B. Dressman, and H. Lennernäs Oral Drug Absorption: Prediction and Assessment 2000 Marcel Dekker New York
13. G. Frieri, G. De Petris, A. Aggio, D. Santarelli, E. Ligas, R. Rosoni, and R. Caprilli Gastric and duodenal juxtamucosal pH and Helicobacter pylori Digestion 56 2 1995 107 110
14. G. Flemstrom, and L.A. Turnberg Gastroduodenal defence mechanisms Clin. Gastroenterol. 13 2 1984 327 354
15. A.W. Larhed, P. Artursson, J. Grasjo, and E. Bjork Diffusion of drugs in native and purified gastrointestinal mucus J. Pharm. Sci. 86 6 1997 660 665
16. N. Jordan, J. Newton, J. Pearson, and A. Allen A novel method for the visualization of the in situ mucus layer in rat and man Clin. Sci. 95 1 1998 97 106
17. J.L. Newton, N. Jordan, L. Oliver, V. Strugala, J. Pearson, O.F.W. James, and A. Allen Helicobacter pylori in vivo causes structural changes in the adherent gastric mucus layer but barrier thickness is not compromised Gut 43 4 1998 470 475
18. J.L. Newton, N. Jordan, J. Pearson, G.V. Williams, A. Allen, and O.F. James The adherent gastric antral and duodenal mucus gel layer thins with advancing age in subjects infected with Helicobacter pylori Gerontology 46 3 2000 153 157
19. J.M. Gu, J.R. Robinson, and S.H. Leung Binding of acrylic polymers to mucin/epithelial surfaces: structure-property relationships Crit. Rev. Ther. Drug Carr. Syst. 5 1 1988 21 67
20. S. Shah, R. Qaqish, V. Patel, and M. Amiji Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection J. Pharm. Pharmacol. 51 6 1999 667 672
21. G.M. Clarke, J.M. Newton, and M.D. Short Gastrointestinal transit of pellets of differing size and density Int. J. Pharm. 100 1-3 1993 81 92
22. J.L. Riner, R.L. Byford, L.G. Stratton, and J.A. Hair Influence of density and location on degradation of sustained-release boluses given to cattle Am. J. Vet. Res. 43 11 1982 2028 2030
23. J.R. Cardinal Controlled drug delivery: veterinary applications J. Control. Release 2 1985 393 403
24. A.J. Moës Gastric retention systems for oral drug delivery Business Briefing: PharmaTech 2003 157 159
25. S. Garg, and S. Sharma Gastroretentive drug delivery systems Business Briefing: PharmaTech 2003 160 166
26. N. Mazer, E. Abisch, J.C. Gfeller, R. Laplanche, P. Bauerfeind, M. Cucala, M. Lukachich, and A. Blum Intragastric behavior and absorption kinetics of a normal and "floating" modified-release capsule of isradipine under fasted and fed conditions J. Pharm. Sci. 77 8 1988 647 657
27. B.N. Singh, and K.H. Kim Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention J. Control. Release 63 3 2000 235 259
28. N. Saito, K. Konishi, F. Sato, M. Kato, H. Takeda, T. Sugiyama, and M. Asaka Plural transformation-processes from spiral to coccoid Helicobacter pylori and its viability J. Infect. 46 1 2003 49 55
29. P. Mojaverian, R.K. Ferguson, P.H. Vlasses, M.L. Rocci Jr., A. Oren, J.A. Fix, L.J. Caldwell, and C. Gardner Estimation of gastric residence time of the Heidelberg capsule in humans: effect of varying food composition Gastroenterology 89 2 1985 392 397
30. L. Whitehead, J.T. Fell, J.H. Collett, H.L. Sharma, and A. Smith Floating dosage forms: an in vivo study demonstrating prolonged gastric retention J. Control. Release 55 1 1998 3 12
31. A. Steingoetter, P. Kunz, D. Weishaupt, K. Mader, H. Lengsfeld, M. Thumshirn, P. Boesiger, M. Fried, and W. Schwizer Analysis of the meal-dependent intragastric performance of a gastric-retentive tablet assessed by magnetic resonance imaging Aliment. Pharmacol. Ther. 18 7 2003 713 720
32. L.H. Reddy, and R.S. Murthy Floating dosage systems in drug delivery Crit. Rev. Ther. Drug Carr. Syst. 19 6 2002 553 585
33. S.J. Hwang, H. Park, and K. Park Gastric retentive drug-delivery systems Crit. Rev. Ther. Drug Carr. Syst. 15 3 1998 243 284
34. W. Erni, and K. Held The hydrodynamically balanced system: a novel principle of controlled drug release Eur. Neurol. 27 Suppl. 1 1987 21 27
35. E.N. Jansen, and J.D. Meerwaldtt Madopar HBS in nocturnal symptoms of Parkinson's disease Adv. Neurol. 53 1990 527 531
36. W.C. Koller, and R. Pahwa Treating motor fluctuations with controlled-release levodopa preparations Neurology 44 7 Suppl. 6 1994 S23 S28
37. M. Oth, M. Franz, J. Timmermans, and A. Moes The bilayer floating capsule: a stomach-directed drug delivery system for misoprostol Pharm. Res. 9 3 1992 298 302
38. S.B. Mitra, Sustained-realase oral medecininal delivery device, US patent 4451260, May 29, 1984.
39. R.M. Harrigan, Drug delivery device for preventing contact of undissolved drug with the stomach lining, US patent 4055178, October 25, 1977.
40. S.K. Gupta, Stability studies of ampicillin floating tablets (Ampiflot) and buffered ampiflot, Masters thesis, St. John's University, New York, 1987.
41. T. Watanabe, M. Kayano, Y. Ishino, K. Miyao, Solid therapeutic preparation remaining in stomach, US patent 3976764, August 24, 1976.
42. V.S. Chitnis, V.S. Malshe, and J.K. Lalla Bioadhesive polymers synthesis, evaluation and application in controlled release tablets Drug Dev. Ind. Pharm. 17 1991 879 892
43. I. Krogel, and R. Bodmeier Development of a multifunctional matrix drug delivery system surrounded by an impermeable cylinder J. Control. Release 61 1-2 1999 43 50
44. A.S. Michaels, Drug delivery device for self actuated mechanism for retaining device in selected area, US patent 3786813, January 22, 1974.
45. A.S. Michaels, Integrated device for administering beneficial drug at programmed rate, US patent 3901232, August 26, 1975.
46. W.A. Ritschel Targeting in the gastrointestinal tract: new approaches Methods Find. Exp. Clin. Pharmacol. 13 5 1991 313 336
47. G.L. Chen, and W.H. Hao In vitro performance of floating sustained-release capsule of verapamil Drug Dev. Ind. Pharm. 24 11 1998 1067 1072
48. S. Baumgartner, J. Kristl, F. Vrecer, P. Vodopivec, and B. Zorko Optimisation of floating matrix tablets and evaluation of their gastric residence time Int. J. Pharm. 195 1-2 2000 125 135
49. G. Xu, and M.J. Groves Effect of FITC-dextran molecular weight on its release from floating cetyl alcohol and HPMC tablets J. Pharm. Pharmacol. 53 1 2001 49 56
50. H.M. Ingani, J. Timmermans, and A.J. Moes Conception and in vivo investigation of peroral sustained release floating dosage forms with enhanced gastrointestinal transit Int. J. Pharm. 35 1-2 1987 157 164
51. A.K. Hilton, and P.B. Deasy In vitro and in vivo evaluation of an oral sustained-release floating dosage form of amoxicillin trihydrate Int. J. Pharm. 86 1 1992 79 88
52. I. Krogel, and R. Bodmeier Floating or pulsatile drug delivery systems based on coated effervescent cores Int. J. Pharm. 187 2 1999 175 184
53. L. Yang, J. Eshraghi, and R. Fassihi A new intragastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation J. Control. Release 57 3 1999 215 222
54. N. Ozdemir, S. Ordu, and Y. Ozkan Studies of floating dosage forms of furosemide: in vitro and in vivo evaluations of bilayer tablet formulations Drug Dev. Ind. Pharm. 26 8 2000 857 866
55. Z. Wei, Z. Yu, and D. Bi Design and evaluation of a two-layer floating tablet for gastric retention using cisapride as a model drug Drug Dev. Ind. Pharm. 27 5 2001 469 474
56. S.Y. Hou, V.E. Cowles, and B. Berner Gastric retentive dosage forms: a review Crit. Rev. Ther. Drug Carr. Syst. 20 6 2003 459 497
57. M. Ichikawa, S. Watanabe, and Y. Miyake A new multiple-unit oral floating dosage system: I. Preparation and in vitro evaluation of floating and sustained-release characteristics J. Pharm. Sci. 80 11 1991 1062 1066
58. M. Ichikawa, T. Kato, M. Kawahara, S. Watanabe, and M. Kayano A new multiple-unit oral floating dosage system: II. In vivo evaluation of floating and sustained-release characteristics with p-aminobenzoic acid and isosorbide dinitrate as model drugs J. Pharm. Sci. 80 12 1991 1153 1156
59. F. Atyabi, H.L. Sharma, H.A.H. Mohammad, and J.T. Fell Controlled drug release from coated floating ion exchange resin beads J. Control. Release 42 1 1996 25 28
60. F. Atyabi, H.L. Sharma, H.A.H. Mohammad, and J.T. Fell In vivo evaluation of a novel gastric retentive formulation based on ion exchange resins J. Control. Release 42 2 1996 105 113
61. N. Washington Investigation into the barrier action of an alginate gastric reflux suppressant, Liquid Gaviscon Drug Investig. 2 1987 23 30
62. J. Foldager, H. Toftkjor, K. Kjornos, Antacid composition, US patent 5068109, November 26, 1991.
63. J.L. Fabregas, J. Claramunt, J. Cucala, R. Pous, and A. Siles In vitro testing of an antiacid formulation with prolonged gastric residence time (Almagate Flot-Coat) Drug Dev. Ind. Pharm. 20 1994 1199 1212
64. T. Havelund, C. Aalykke, and L. Rasmussen Efficacy of a pectin-based anti-reflux agent on acid reflux and recurrence of symptoms and oesophagitis in gastro-oesophageal reflux disease Eur. J. Gastroenterol. Hepatol. 9 5 1997 509 514
65. Y. Kawashima, T. Niwa, H. Takeuchi, T. Hino, and Y. Itoh Hollow microspheres for use as a floating controlled drug delivery system in the stomach J. Pharm. Sci. 81 2 1992 135 140
66. G. Jayanthi, S.B. Jayaswal, and A.K. Srivastava Formulation and evaluation of terfenadine microballoons for oral controlled release Pharmazie 50 11 1995 769 770
67. Y. Sato, Y. Kawashima, H. Takeuchi, and H. Yamamoto In vivo evaluation of riboflavin-containing microballoons for floating controlled drug delivery system in healthy human volunteers J. Control. Release 93 1 2003 39 47
68. Y. Sato, Y. Kawashima, H. Takeuchi, and H. Yamamoto In vitro and in vivo evaluation of riboflavin-containing microballoons for a floating controlled drug delivery system in healthy humans Int. J. Pharm. 275 1-2 2004 97 107
69. Y. Sato, Y. Kawashima, H. Takeuchi, H. Yamamoto, and Y. Fujibayashi Pharmacoscintigraphic evaluation of riboflavin-containing microballoons for a floating controlled drug delivery system in healthy humans J. Control. Release 98 1 2004 75 85
70. A. Streubel, J. Siepmann, and R. Bodmeier Floating microparticles based on low density foam powder Int. J. Pharm. 241 2 2002 279 292
71. B.C. Thanoo, M.C. Sunny, and A. Jayakrishnan Oral sustained-release drug delivery systems using polycarbonate microspheres capable of floating on the gastric fluid J. Pharm. Pharmacol. 45 1 1993 21 24
72. S. Stithit, W. Chen, and J.C. Price Development and characterization of buoyant theophylline microspheres with near zero order release kinetics J. Microencapsul 15 6 1998 725 737
73. A. Streubel, J. Siepmann, and R. Bodmeier Floating matrix tablets based on low density foam powder: effects of formulation and processing parameters on drug release Eur. J. Pharm. Sci. 18 1 2003 37 45
74. R. Talukder, and R. Fassihi Gastroretentive delivery systems: hollow beads Drug Dev. Ind. Pharm. 30 4 2004 405 412
75. E.A. Klausner, E. Lavy, M. Friedman, and A. Hoffman Expandable gastroretentive dosage forms J. Control. Release 90 2 2003 143 162
76. L.J. Caldwell, C.R. Gardner, R.C. Cargill, Drug delivery device which can be retained in the stomach for a controlled period of time, US patent 4735804, April 5, 1988.
77. L.J. Caldwell, C. Gardner, R.C. Cargill, T. Higuchi, Drug delivery device which can be retained in the stomach for a controlled period of time, US patent 4758436, July 19, 1988.
78. W.J. Curatolo, J. Lo, Gastric retention drug system for controlled drug release, US patent 5443843, August 22, 1995.
79. T. Sonobe, S. Watanabe, M. Katsuma, N. Takamatsu, Y. Konno, H. Takagi, Gastric retention device, Eur. patent 0415671, March 13, 1991.
80. E.A. Klausner, S. Eyal, E. Lavy, M. Friedman, and A. Hoffman Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs J. Control. Release 88 1 2003 117 126
81. E.A. Klausner, E. Lavy, M. Barta, E. Cserepes, M. Friedman, and A. Hoffman Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans Pharm. Res. 20 9 2003 1466 1473
82. J. Urquhart, F. Theeuwes, Drug delivery system comprising a reservoir containing a plurality of tiny pills, US patent 4434153, February 28, 1984.
83. R.C. Mamajek, E.S. Moyer, Drug-dispensing device and method, US patent 4207890, June 17, 1980.
84. F. Kedzierewicz, P. Thouvenot, J. Lemut, A. Etienne, M. Hoffman, and P. Maincent Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy J. Control. Release 58 2 1999 195 205
85. J. Chen, W.E. Blevins, H. Park, and K. Park Gastric retention properties of superporous hydrogel composites J. Control. Release 64 1-3 2000 39 51
86. J. Chen, and K. Park Synthesis and characterization of superporous hydrogel composites J. Control. Release 65 1-2 2000 73 82
87. J. Gutierrez-Rocca, H. Omidian, and K. Shah Progresses in gastroretentive drug delivery systems Business Briefing: PharmaTech 2003 152 156
88. K. Park, and J.R. Robinson Bioadhesive polymers as platforms for oral-controlled drug delivery: method to study bioadhesion Int. J. Pharm. 19 2 1984 107 127
89. J.D. Smart, I.W. Kellaway, and H.E. Worthington An in-vitro investigation of mucosa-adhesive materials for use in controlled drug delivery J. Pharm. Pharmacol. 36 5 1984 295 299
90. Y. Huang, W. Leobandung, A. Foss, and N.A. Peppas Molecular aspects of muco- and bioadhesion: tethered structures and site-specific surfaces J. Control. Release 65 1-2 2000 63 71
91. J.K. Vasir, K. Tambwekar, and S. Garg Bioadhesive microspheres as a controlled drug delivery system Int. J. Pharm. 255 1-2 2003 13 32
92. V. Faivre Aspects théoriques de la bioadhésion F. Falson-Rieg V. Faivre F. Pirot Nouvelles formes médicamenteuses, Éditions Médicales Internationales 2004 Éditions TEC and DOC Cachan 1 24
93. S. Kockisch, G.D. Rees, S.A. Young, J. Tsibouklis, and J.D. Smart Polymeric microspheres for drug delivery to the oral cavity: an in vitro evaluation of mucoadhesive potential J. Pharm. Sci. 92 8 2003 1614 1623
94. Y. Akiyama, N. Nagahara, T. Kashihara, S. Hirai, and H. Toguchi In vitro and in vivo evaluation of mucoadhesive microspheres prepared for the gastrointestinal tract using polyglycerol esters of fatty acids and a poly(acrylic acid) derivative Pharm. Res. 12 3 1995 397 405
95. Y. Akiyama, N. Nagahara, E. Nara, M. Kitano, S. Iwasa, I. Yamamoto, J. Azuma, and Y. Ogawa Evaluation of oral mucoadhesive microspheres in man on the basis of the pharmacokinetics of furosemide and riboflavin, compounds with limited gastrointestinal absorption sites J. Pharm. Pharmacol. 50 2 1998 159 166
96. V.R. Sinha, A.K. Singla, S. Wadhawan, R. Kaushik, R. Kumria, K. Bansal, and S. Dhawan Chitosan microspheres as a potential carrier for drugs Int. J. Pharm. 274 1-2 2004 1 33
97. R. Hejazi, and M. Amiji Stomach-specific anti-H. pylori therapy: II. Gastric residence studies of tetracycline-loaded chitosan microspheres in gerbils Pharm. Dev. Technol. 8 3 2003 253 262
98. M. Sakkinen, J. Marvola, H. Kanerva, K. Lindevall, M. Lipponen, T. Kekki, A. Ahonen, and M. Marvola Gamma scintigraphic evaluation of the fate of microcrystalline chitosan granules in human stomach Eur. J. Pharm. Biopharm. 57 1 2004 133 143
99. R. Hejazi, and M. Amiji Stomach-specific anti-H. pylori therapy: Part III. Effect of chitosan microspheres crosslinking on the gastric residence and local tetracycline concentrations in fasted gerbils Int. J. Pharm. 272 1-2 2004 99 108
100. P. Giunchedi, I. Genta, B. Conti, R.A. Muzzarelli, and U. Conte Preparation and characterization of ampicillin loaded methylpyrrolidinone chitosan and chitosan microspheres Biomaterials 19 1-3 1998 157 161
101. S. Torrado, P. Prada, and P.M. De La Torre Chitosan-poly(acrylic) acid polyionic complex: in vivo study to demonstrate prolonged gastric retention Biomaterials 25 5 2004 917 923
102. H. Kodaira, K. Ishihara, K. Hotta, M. Kagoshima, H. Shimada, and K. Ishii Reaction of various lectins to mucin derived from the different layers of rat gastric mucosa: comparison of enzyme-linked lectin binding assay with lectin histochemistry Biol. Pharm. Bull. 23 10 2000 1173 1179
103. B. Naisbett, and J. Woodley The potential use of tomato lectin for oral drug delivery: 1. Lectin binding to rat small intestine in vitro Int. J. Pharm. 107 3 1994 223 230
104. B. Naisbett, and J. Woodley The potential use of tomato lectin for oral drug delivery: 2. Mechanism of uptake in vitro Int. J. Pharm. 110 2 1994 127 136
105. B. Naisbett, and J. Woodley The potential use of tomato lectin for oral drug delivery: 3. Bioadhesion in vivo Int. J. Pharm. 114 2 1995 227 236
106. C. Bies, C.-M. Lehr, and J.F. Woodley Lectin-mediated drug targeting: history and applications Adv. Drug Deliv. Rev. 56 4 2004 425 435
107. M.J. Montisci, G. Giovannuci, D. Duchene, and G. Ponchel Covalent coupling of asparagus pea and tomato lectins to poly(lactide) microspheres Int. J. Pharm. 215 1-2 2001 153 161
108. C.M. Lehr, J.A. Bouwstra, W. Kok, A.B. Noach, A.G. De Boer, and H.E. Junginger Bioadhesion by means of specific binding of tomato lectin Pharm. Res. 9 4 1992 547 553
109. J.M. Irache, C. Durrer, D. Duchene, and G. Ponchel Preparation and characterization of lectin-latex conjugates for specific bioadhesion Biomaterials 15 11 1994 899 904
110. J.M. Irache, C. Durrer, D. Duchene, and G. Ponchel Bioadhesion of lectin-latex conjugates to rat intestinal mucosa Pharm. Res. 13 11 1996 1716 1719
111. R. Ito, Y. Machida, T. Sannan, and T. Nagai Magnetic granules: a novel system for specific drug delivery to esophageal mucosa in oral administration Int. J. Pharm. 61 1-2 1990 109 117
112. J. Fujimori, Y. Machida, and T. Nagai Preparation of a magnetically-responsive tablet and confirmation of its gastric residence in beagle dogs STP Pharma Sci. 4 1994 425 430
113. R. Groning, and M. Berntgen Estimation of the gastric residence time of magnetic dosage forms using the Heidelberg capsule Pharmazie 51 5 1996 328 331
114. R. Groning, M. Berntgen, and M. Georgarakis Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extracorporal magnets to control gastrointestinal transit Eur. J. Pharm. Biopharm. 46 3 1998 285 291
115. C.G. Wilson, N. Washington, J.L. Greaves, F. Kamali, J.A. Rees, A.K. Sempik, and J.F. Lampard Bimodal release of ibuprofen in a sustained-release formulation: a scintigraphic and pharmacokinetic open study in healthy volunteers under different conditions of food intake Int. J. Pharm. 50 2 1989 155 161
116. H.P. Parkman, D.M. Trate, L.C. Knight, K.L. Brown, A.H. Maurer, and R.S. Fisher Cholinergic effects on human gastric motility Gut 45 3 1999 346 354
117. G. Mikus, B. Trausch, C. Rodewald, U. Hofmann, K. Richter, T. Gramatte, and M. Eichelbaum Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype Clin. Pharmacol. Ther. 61 4 1997 459 466
118. M.A. Boivin, M.C. Carey, and H. Levy Erythromycin accelerates gastric emptying in a dose-response manner in healthy subjects Pharmacotherapy 23 1 2003 5 8
119. P. Mojaverian, P.H. Vlasses, P.E. Kellner, and M.L. Rocci Jr. Effects of gender, posture, and age on gastric residence time of an indigestible solid: pharmaceutical considerations Pharm. Res. 5 10 1988 639 644
120. J.L. Madsen, and J. Graff Effects of ageing on gastrointestinal motor function Age Ageing 33 2 2004 154 159
121. D.S. Smith, and C.D. Ferris Current concepts in diabetic gastroparesis Drugs 63 13 2003 1339 1358
122. B. Marshall Helicobacter pylori: 20 years on Clin. Med. 2 2 2002 147 152
123. R. Mc Loughlin, I. Racz, M. Buckley, H.J. O'connor, and C. O'morain Therapy of Helicobacter pylori Helicobacter 9 Suppl. 1 2004 42 48
124. K. Shinohara, K. Miyazaki, N. Noda, D. Saitoh, M. Terada, and H. Wakasugi Gastric diseases related to Helicobacter pylori and Epstein-Barr virus infection Microbiol. Immunol. 42 6 1998 415 421
125. Y.Q. Sun, J.D. Soderholm, F. Petersson, and K. Borch Long-standing gastric mucosal barrier dysfunction in Helicobacter pylori-induced gastritis in mongolian gerbils Helicobacter 9 3 2004 217 227
126. R.W. Goodgame, H.M. Malaty, H.M. El-Zimaity, and D.Y. Graham Decrease in gastric permeability to sucrose following cure of Helicobacter pylori infection Helicobacter 2 1 1997 44 47
127. K. Borch, C. Sjostedt, U. Hannestad, J.D. Soderholm, L. Franzen, and S. Mardh Asymptomatic Helicobacter pylori gastritis is associated with increased sucrose permeability Dig. Dis. Sci. 43 4 1998 749 753
128. L.A. Noach, T.M. Rolf, and G.N. Tytgat Electron microscopic study of association between Helicobacter pylori and gastric and duodenal mucosa J. Clin. Pathol. 47 8 1994 699 704
129. Z. Posalaky, I. Posalaky, D. Mcginley, and R.A. Meyer The gastric mucosal barrier: tight junction structure in gastritis and ulcer biopsies Virchows Arch., A Pathol. Anat. Histopathol. 414 3 1989 217 222
130. J.C. Byrd, C.K. Yunker, Q.S. Xu, L.R. Sternberg, and R.S. Bresalier Inhibition of gastric mucin synthesis by Helicobacter pylori Gastroenterology 118 6 2000 1072 1079
131. J.C. Byrd, and R.S. Bresalier Alterations in gastric mucin synthesis by Helicobacter pylori World J. Gastroenterol. 6 4 2000 475 482
132. S. Tanaka, M. Mizuno, T. Maga, F. Yoshinaga, J. Tomoda, J. Nasu, H. Okada, K. Yokota, K. Oguma, Y. Shiratori, and T. Tsuji H. pylori decreases gastric mucin synthesis via inhibition of galactosyltransferase Hepato-gastroenterol. 50 53 2003 1739 1742
133. H. Suzuki, and H. Ishii Role of apoptosis in Helicobacter pylori-associated gastric mucosal injury J. Gastroenterol. Hepatol. 15 2000 D46 D54 (Suppl.)
134. F.S. Lehmann, L. Terracciano, I. Carena, C. Baeriswyl, J. Drewe, L. Tornillo, G. De Libero, and C. Beglinger In situ correlation of cytokine secretion and apoptosis in Helicobacter pylori-associated gastritis Am. J. Physiol.: Gasterointest. Liver Physiol. 283 2 2002 G481 G488
135. S. Maeda, H. Yoshida, Y. Mitsuno, Y. Hirata, K. Ogura, Y. Shiratori, and M. Omata Analysis of apoptotic and antiapoptotic signalling pathways induced by Helicobacter pylori Gut 50 6 2002 771 778
136. A. Potthoff, S. Ledig, J. Martin, O. Jandl, M. Cornberg, B. Obst, W. Beil, M.P. Manns, and S. Wagner Significance of the caspase family in Helicobacter pylori induced gastric epithelial apoptosis Helicobacter 7 6 2002 367 377
137. E. Papini, M. Zoratti, and T.L. Cover In search of the Helicobacter pylori VacA mechanism of action Toxicon 39 11 2001 1757 1767
138. T.G. Blanchard, M.L. Drakes, and S.J. Czinn Helicobacter infection: pathogenesis Curr. Opin. Gastroenterol. 20 1 2004 10 15
139. M.S. Ladeira, M.A. Rodrigues, D.M. Salvadori, P.P. Neto, P. Achilles, M.M. Lerco, P.A. Rodrigues, I. Goncalves Jr., D.M. Queiroz, and D.V. Freire-Maia Relationships between cagA, vacA, and iceA genotypes of Helicobacter pylori and DNA damage in the gastric mucosa Environ. Mol. Mutagen. 44 2 2004 91 98
140. C. Pagliaccia, X.M. Wang, F. Tardy, J.L. Telford, J.M. Ruysschaert, and V. Cabiaux Structure and interaction of VacA of Helicobacter pylori with a lipid membrane Eur. J. Biochem. 267 1 2000 104 109
141. S. Suerbaum, and P. Michetti Helicobacter pylori infection N. Engl. J. Med. 347 15 2002 1175 1186
142. M. Contreras, and A. Labigne Quels sont les facteurs de virulence de Helicobacter pylori? Gastroenterol. Clin. Biol. 27 3 Pt. 2 2003 401 408
143. J. Henriksnäs, M. Phillipson, L. Engstrand, and L. Holm Digestive pathophysiology (secretion, motility, permeability). Abstract N°05.02: Helicobacter pylori infection reduces the firmly adherent gastric mucus gel and the ability to maintain pH neutral at the surface of the epithelial cells in mice Helicobacter 8 4 2003 382 385
144. K.E. Mc Coll Helicobacter pylori and acid secretion: where are we now? Eur. J. Gastroenterol. Hepatol. 9 4 1997 333 335
145. E.M. El-Omar, K. Oien, A. El-Nujumi, D. Gillen, A. Wirz, S. Dahill, C. Williams, J.E. Ardill, and K.E. Mccoll Helicobacter pylori infection and chronic gastric acid hyposecretion Gastroenterology 113 1 1997 15 24
146. K. Iijima, H. Sekine, T. Koike, A. Imatani, S. Ohara, and T. Shimosegawa Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria Aliment. Pharmacol. Ther. 19 11 2004 1181 1188
147. F.Y. Chang, C.L. Lu, C.Y. Chen, J.C. Luo, K.L. Jium, and S.D. Lee Effect of Helicobacter pylori eradicated therapy on water gastric emptying in patients with active duodenal ulcer J. Gastroenterol. Hepatol. 18 11 2003 1250 1256
148. J.W. Konturek, R. Stoll, J. Menzel, M. Konturek, S.J. Konturek, and W. Domschke Eradication of Helicobacter pylori restores the inhibitory effect of cholecystokinin on gastric motility in duodenal ulcer patients Scand. J. Gastroenterol. 36 3 2001 241 246
149. G.I. Leontiadis, G.I. Minopoulos, E. Maltezos, S. Kotsiou, K.I. Manolas, K. Simopoulos, and D. Hatseras Effects of Helicobacter pylori infection on gastric emptying rate in patients with non-ulcer dyspepsia World J. Gastroenterol. 10 12 2004 1750 1754
150. P.W. Dettmar, J.G. Lloyd-Jones, Method of treatment of Heliobacter pylori infections with triclosan, US patent 5286492, February 15, 1994.
151. S. Skouloubris, H. De Reuse, and A. Labigne Bactériologie et pathogénicité d'Helicobacter pylori Rev. Prat. 50 2000 1409 1413
152. R.B. Umamaheshwari, S. Jain, D. Bhadra, and N.K. Jain Floating microspheres bearing acetohydroxamic acid for the treatment of Helicobacter pylori J. Pharm. Pharmacol. 55 12 2003 1607 1613
153. R.B. Umamaheshwari, and N.K. Jain Receptor-mediated targeting of lipobeads bearing acetohydroxamic acid for eradication of Helicobacter pylori J. Control. Release 99 1 2004 27 40
154. R.B. Umamaheshwari, S. Jain, P.K. Tripathi, G.P. Agrawal, and N.K. Jain Floating-bioadhesive microspheres containing acetohydroxamic acid for clearance of Helicobacter pylori Drug Deliv. 9 4 2002 223 231
155. R.B. Umamaheshwari, S. Jain, and N.K. Jain A new approach in gastroretentive drug delivery system using cholestyramine Drug Deliv. 10 3 2003 151 160
156. N. Nagahara, Y. Akiyama, M. Nakao, M. Tada, M. Kitano, and Y. Ogawa Mucoadhesive microspheres containing amoxicillin for clearance of Helicobacter pylori Antimicrob. Agents Chemother. 42 10 1998 2492 2494
157. Z. Liu, W. Lu, L. Qian, X. Zhang, P. Zeng, and J. Pan In vitro and in vivo studies on mucoadhesive microspheres of amoxicillin J. Control. Release 102 1 2005 135 144
158. H. Katayama, T. Nishimura, S. Ochi, Y. Tsuruta, Y. Yamazaki, K. Shibata, and H. Yoshitomi Sustained release liquid preparation using sodium alginate for eradication of Helicobacter pyroli Biol. Pharm. Bull. 22 1 1999 55 60
159. D. Ilver, A. Arnqvist, J. Ogren, I.M. Frick, D. Kersulyte, E.T. Incecik, D.E. Berg, A. Covacci, L. Engstrand, and T. Boren Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging Science 279 5349 1998 373 377
160. Y.H. An, and R.J. Friedman Handbook of Bacterial Adhesion. Principles, Methods, and Applications 2000 Humana Press Inc. Totowa
161. R.B. Umamaheshwari, P. Jain, and N.K. Jain Site specific drug delivery of acetohydroxamic acid for treatment of H. pylori STP Pharma Sci. 13 1 2003 41 48
162. C. Lingwood, M. Huesca, and A. Kuksis The glycerolipid receptor for Helicobacter pylori (and exoenzyme S) is phosphatidylethanolamine Infect. Immun. 60 6 1992 2470 2474
163. C.A. Lingwood H. pylori adhesins and receptors S. Goodwin B.W. Worsley Helicobacter pylori: Biology and Clinical Practice 1993 CRC Press, Inc Boca Raton 209 222
164. M. Huesca, S. Borgia, P. Hoffman, and C.A. Lingwood Acidic pH changes receptor binding specificity of Helicobacter pylori: a binary adhesion model in which surface heat shock (stress) proteins mediate sulfatide recognition in gastric colonization Infect. Immun. 64 7 1996 2643 2648
165. W.Y. Chan, P.K. Hui, K.M. Leung, J. Chow, F. Kwok, and C.S. Ng Coccoid forms of Helicobacter pylori in the human stomach Am. J. Clin. Pathol. 102 4 1994 503 507
166. B. Janas, E. Czkwianianc, L. Bak-Romaniszyn, H. Bartel, D. Tosik, and I. Planeta-Malecka Electron microscopic study of association between coccoid forms of Helicobacter pylori and gastric epithelial cells Am. J. Gastroenterol. 90 10 1995 1829 1833
167. J.G. Kusters, M.M. Gerrits, J.A. Van Strijp, and C.M. Vandenbroucke-Grauls Coccoid forms of Helicobacter pylori are the morphologic manifestation of cell death Infect. Immun. 65 9 1997 3672 3679
168. M. Benaissa, P. Babin, N. Quellard, L. Pezennec, Y. Cenatiempo, and J.L. Fauchere Changes in Helicobacter pylori ultrastructure and antigens during conversion from the bacillary to the coccoid form Infect. Immun. 64 6 1996 2331 2335
169. H.O. Nilsson, J. Blom, W. Abu-Al-Soud, A.A. Ljungh, L.P. Andersen, and T. Wadstrom Effect of cold starvation,1 acid stress, and nutrients on metabolic activity of Helicobacter pylori Appl. Environ. Microbiol. 68 1 2002 11 19
170. T. Osaki, H. Yamaguchi, H. Taguchi, M. Fukada, H. Kawakami, H. Hirano, and S. Kamiya Interleukin-8 induction and adhesion of the coccoid form of Helicobacter pylori J. Med. Microbiol. 51 4 2002 295 299
171. A. Nakamura, A. Park, K. Nagata, E.F. Sato, M. Kashiba, T. Tamura, and M. Inoue Oxidative cellular damage associated with transformation of Helicobacter pylori from a bacillary to a coccoid form Free Radic. Biol. Med. 28 11 2000 1611 1618
172. M.I. Brenciaglia, A.M. Fornara, M.M. Scaltrito, and F. Dubini Helicobacter pylori: cultivability and antibiotic susceptibility of coccoid forms Int. J. Antimicrob. Agents 13 4 2000 237 241
173. M. Sorberg, M. Nilsson, H. Hanberger, and L.E. Nilsson Morphologic conversion of Helicobacter pylori from bacillary to coccoid form Eur. J. Clin. Microbiol. Infect. Dis. 15 3 1996 216 219
174. F. Sisto, M.I. Brenciaglia, M.M. Scaltrito, and F. Dubini Helicobacter pylori: ureA, cagA and vacA expression during conversion to the coccoid form Int. J. Antimicrob. Agents 15 4 2000 277 282
175. M.M. Khin, J.S. Hua, H.C. Ng, T. Wadstrom, and H. Bow Agglutination of Helicobacter pylori coccoids by lectins World J. Gastroenterol. 6 2 2000 202 209